Strategies for Mitigating Immunogenicity and Controlling Inflammation: Bridging Preclinical Insights with Clinical Translation
17 Jun 2025
Immunogenicity
- What are the common immunogenicity risks across different biotherapeutic modalities (monoclonal antibodies, cell therapies, and gene therapies)?
- Is it possible to selectively suppress immune responses in an antigen-specific manner, or is systemic immunosuppression always necessary?
- Can you use similar mitigation strategies across different Biotherapeutic modalities?
- How relevant are preclinical studies to clinical translation—and are we approaching a point where they can be reconsidered or replaced?
- What key lessons have we learned from the development and clinical use of biotherapeutic modalities in treating cancer, autoimmune disorders, and rare diseases?
